절제 불가능 간세포암 시장 - 세계 예측(2026-2032년)

The Unresectable Hepatocellular Carcinoma Market is projected to grow by USD 5.35 billion at a CAGR of 13.79% by 2032.

Unresectable hepatocellular carcinoma represents a critical segment of liver cancer care, defined by tumors that cannot be removed surgically because of tumor burden, vascular invasion, multifocal disease, poor liver reserve, or advanced underlying cirrhosis. Hepatocellular carcinoma is the most common primary liver cancer and is strongly associated with chronic hepatitis B, chronic hepatitis C, alcohol-related liver disease, metabolic dysfunction-associated steatotic liver disease, aflatoxin exposure, and cirrhosis. Verified public health evidence from global cancer and liver disease authorities consistently identifies liver cancer among the leading causes of cancer mortality worldwide, with a high proportion of patients diagnosed beyond curative surgical eligibility.

The treatment paradigm for unresectable hepatocellular carcinoma has moved beyond single-modality care toward integrated systemic therapy, locoregional therapy, imaging-driven assessment, and multidisciplinary tumor board decision-making. Immune checkpoint inhibitor combinations, anti-angiogenic strategies, tyrosine kinase inhibitors, radioembolization, transarterial chemoembolization, external beam radiotherapy, ablation in select cases, and best supportive care are increasingly considered within patient-specific pathways. Key industry priorities include improving real-world treatment sequencing, expanding access to biomarker-informed care, reducing time to diagnosis, supporting liver cancer surveillance among high-risk populations, and preserving liver function while pursuing durable tumor control.

Transformative Shifts in the Treatment Landscape

The unresectable hepatocellular carcinoma landscape is undergoing transformative change as clinical practice shifts from uniform systemic treatment to more individualized and multidisciplinary management. International liver cancer guidelines increasingly emphasize liver function, performance status, tumor burden, macrovascular invasion, extrahepatic spread, portal hypertension, and patient preference when selecting treatment. This has elevated the role of hepatology, interventional radiology, oncology, radiation oncology, pathology, palliative care, and transplant expertise in coordinated care.

A major shift is the growing use of immunotherapy-based combinations as preferred first-line options for eligible patients, supported by phase III evidence showing survival and response advantages over older systemic standards in defined populations. At the same time, targeted therapies remain essential for patients who are ineligible for immunotherapy, have autoimmune disease, require later-line treatment, or experience progression. Locoregional therapies are also being refined through selective delivery, dosimetry, combination strategies, and better patient selection. The emergence of combination approaches involving systemic therapy with transarterial or radiation-based interventions is creating new clinical questions around timing, safety, hepatic decompensation risk, bleeding risk, and durable response assessment.

Another defining shift is the growing importance of surveillance and early detection. Many patients with hepatocellular carcinoma are diagnosed at stages where curative surgery is not feasible, particularly when cirrhosis surveillance is inconsistent. Health systems are therefore focusing on ultrasound-based surveillance, alpha-fetoprotein testing where appropriate, hepatitis B vaccination, antiviral treatment for hepatitis B and hepatitis C, alcohol harm reduction, and metabolic liver disease management. These preventive and diagnostic strategies directly influence the future clinical burden of unresectable disease.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly influencing unresectable hepatocellular carcinoma across the care continuum, from risk stratification and imaging interpretation to treatment planning and clinical workflow optimization. In high-risk liver disease populations, AI-enabled models can integrate demographics, laboratory values, viral hepatitis status, fibrosis markers, imaging signals, and longitudinal clinical data to support earlier identification of patients needing intensified surveillance. In radiology, deep learning and radiomics approaches are being studied to improve lesion detection, liver segmentation, tumor characterization, vascular invasion assessment, and differentiation between viable tumor and post-treatment necrosis.

AI also has practical implications for locoregional and radiation-based treatment planning. Automated tumor and organ-at-risk contouring, image registration, dose optimization, and response quantification can help standardize workflows and reduce interobserver variability. In systemic therapy, machine learning may support prediction of treatment response, immune-related adverse event risk, liver decompensation, and treatment discontinuation, although clinical adoption depends on external validation, transparent model design, regulatory compliance, privacy protection, and integration into electronic health records.

The cumulative impact of AI is strongest when it improves decision confidence rather than replacing clinical judgment. For industry stakeholders, the most important opportunities are validated AI tools that support hepatocellular carcinoma surveillance, multidisciplinary case review, real-world evidence generation, trial matching, biomarker discovery, toxicity monitoring, and patient follow-up. Key barriers remain data heterogeneity, limited representation of diverse liver disease etiologies, inconsistent imaging protocols, fragmented data systems, algorithm bias, and the need for prospective clinical utility evidence.

Key Regional Insights

Asia-Pacific carries a substantial hepatocellular carcinoma burden because chronic hepatitis B infection remains highly prevalent in several countries, while hepatitis C, alcohol-related liver disease, aflatoxin exposure in selected areas, and metabolic liver disease also contribute. The region's large at-risk population, differences in vaccination coverage, variable access to surveillance, and uneven availability of advanced systemic and locoregional therapies shape outcomes in unresectable disease. China, Japan, South Korea, India, Australia, and ASEAN countries demonstrate highly diverse care environments, ranging from advanced imaging, radioembolization, transarterial procedures, and immunotherapy access to resource-constrained pathways where diagnosis may occur late.

North America is characterized by strong specialist infrastructure, broad use of guideline-based systemic therapy, access to interventional radiology, and expanding attention to liver cancer linked to metabolic dysfunction-associated steatotic liver disease. The United States and Canada benefit from established oncology and hepatology networks, although disparities persist by insurance status, geography, Indigenous health inequities, rural access, transplant referral variation, and viral hepatitis screening gaps. Latin America faces a mixed epidemiologic profile, with hepatitis B, hepatitis C, alcohol-related liver disease, obesity, diabetes, and uneven surveillance contributing to advanced-stage presentation. Brazil and Mexico are important regional care centers, but access to high-cost therapies, molecular diagnostics, advanced imaging, and specialized liver cancer services remains inconsistent.

Europe has a mature hepatocellular carcinoma care ecosystem supported by liver cancer guidelines, multidisciplinary tumor boards, viral hepatitis elimination initiatives, cancer registries, and established reimbursement structures in many countries. However, southern and eastern parts of the region continue to face varied access to screening and advanced therapy. The Middle East shows growing need for specialized liver cancer care as hepatitis-related disease, fatty liver disease, diabetes, and obesity converge, while GCC countries are investing in tertiary oncology, interventional radiology, and transplant-linked infrastructure. Africa faces the most pronounced access challenges, including high hepatitis B prevalence in many areas, aflatoxin exposure in selected regions, limited surveillance, constrained pathology and imaging capacity, insufficient antiviral access, and delayed diagnosis, making prevention, vaccination, antiviral treatment, and scalable diagnostics central to reducing unresectable hepatocellular carcinoma impact.

Key Group Insights

ASEAN countries represent a diverse hepatocellular carcinoma environment where hepatitis B remains an important driver in several populations, while hepatitis C, alcohol use, diabetes, obesity, aflatoxin exposure in selected settings, and variable surveillance systems influence diagnosis and treatment pathways. Urban tertiary centers are increasingly capable of delivering immunotherapy, targeted therapy, transarterial procedures, radiation-based treatment, and advanced imaging, but rural access, out-of-pocket costs, and affordability continue to shape outcomes. Coordinated vaccination, antiviral treatment, cirrhosis surveillance, and liver disease screening remain decisive for reducing late-stage and unresectable presentation.

The GCC is marked by rapid healthcare infrastructure development, increasing oncology specialization, and a rising burden of metabolic liver disease linked to obesity and diabetes, alongside viral hepatitis among some populations. These countries are strengthening tertiary cancer centers, digital health infrastructure, and cross-border referral pathways, creating opportunities for standardized multidisciplinary hepatocellular carcinoma care. The European Union benefits from structured regulatory frameworks, guideline harmonization, hepatitis elimination strategies, health technology assessment processes, and clinical research networks that support consistent adoption of evidence-based therapies, although reimbursement timelines and access to innovative treatment can vary between member states.

BRICS countries collectively account for a large share of the global population at risk for liver cancer, with China and India playing central roles because of population scale and viral hepatitis burden, while Brazil, Russia, and South Africa add distinct patterns involving hepatitis, alcohol-related liver disease, metabolic disease, aflatoxin exposure in selected regions, and healthcare access variability. The G7 group is characterized by advanced oncology systems, strong trial participation, high imaging capability, established pharmacovigilance systems, and increasing focus on real-world evidence, yet it is also experiencing rising hepatocellular carcinoma linked to metabolic liver disease and aging populations. NATO countries overlap with many high-income health systems and emphasize security of pharmaceutical supply chains, clinical readiness, digital health infrastructure, and cross-border research collaboration, all of which affect access and resilience in advanced liver cancer care.

Key Country Insights

The United States has a complex unresectable hepatocellular carcinoma landscape driven by hepatitis C legacy infections, alcohol-related liver disease, metabolic dysfunction-associated steatotic liver disease, obesity, diabetes, and disparities in surveillance access. Canada emphasizes universal healthcare pathways and specialist referral networks, but geographic distance and access for Indigenous and remote communities remain important considerations. Mexico and Brazil face growing metabolic risk factors alongside viral hepatitis and alcohol-related liver disease, with advanced-stage diagnosis often linked to uneven screening, fragmented referral pathways, and specialist availability.

In Europe, the United Kingdom, Germany, France, Italy, and Spain have established hepatology-oncology collaboration, interventional radiology capacity, liver imaging expertise, and access to guideline-supported systemic therapy, while each country faces increasing liver cancer relevance from obesity, diabetes, alcohol use, and an aging population. Germany and France are notable for strong tertiary care and research infrastructure, Italy and Spain have significant cirrhosis-linked hepatocellular carcinoma experience, and the United Kingdom continues to focus on earlier diagnosis, hepatitis C elimination, and reducing regional cancer care variation. Russia has a mixed burden involving viral hepatitis, alcohol-related liver disease, and variable access to advanced diagnostics and therapies across regions.

China remains one of the most important countries for unresectable hepatocellular carcinoma because chronic hepatitis B has historically contributed heavily to liver cancer incidence, although vaccination and antiviral strategies are changing long-term risk patterns. India faces a broad and heterogeneous burden involving hepatitis B, hepatitis C, alcohol-related liver disease, and metabolic risk, with access differences between metropolitan tertiary centers and smaller cities or rural areas. Japan has extensive experience in surveillance, imaging, locoregional therapy, and systemic treatment, with a historical hepatitis C burden and a growing metabolic liver disease component. Australia benefits from advanced cancer care infrastructure and guideline-based access, while continuing to address liver cancer risks among viral hepatitis populations, people with metabolic liver disease, Aboriginal and Torres Strait Islander communities, and other underserved groups. South Korea has strong national screening practices for high-risk groups, advanced hospital infrastructure, and a significant clinical focus on hepatitis B-associated hepatocellular carcinoma.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence-based strategies that improve patient identification, treatment sequencing, access, and measurable outcomes in unresectable hepatocellular carcinoma. The first priority is strengthening surveillance and referral pathways for patients with cirrhosis, chronic hepatitis B, chronic hepatitis C, alcohol-related liver disease, and metabolic dysfunction-associated steatotic liver disease. Earlier detection can reduce the proportion of patients entering care with advanced, unresectable disease and can improve eligibility for curative or disease-controlling interventions.

Stakeholders should invest in multidisciplinary care models that connect hepatology, oncology, interventional radiology, radiology, pathology, palliative care, transplant services, clinical pharmacy, and nursing navigation. Treatment algorithms should reflect liver function, bleeding risk, autoimmune status, portal hypertension, tumor stage, patient goals, and local treatment availability. Real-world evidence programs should be designed to evaluate sequencing after immunotherapy-based regimens, outcomes in Child-Pugh B populations, tolerability in older adults, management of immune-related toxicities, quality-of-life outcomes, and integration of locoregional therapy with systemic treatment.

Additional priorities include expanding biomarker research, validating AI-enabled imaging and risk prediction tools, improving clinical trial diversity, supporting hepatitis B vaccination and antiviral treatment, reducing financial toxicity, strengthening patient navigation, and ensuring patient education around treatment expectations and adverse event reporting. Leaders should also build resilient supply chains for essential oncology drugs, contrast imaging, interventional radiology materials, radiation planning resources, diagnostic testing, and supportive care therapies to reduce interruptions in advanced liver cancer management.

Research Methodology

A rigorous research methodology for unresectable hepatocellular carcinoma should combine secondary evidence review, primary expert validation, and structured analysis of clinical, epidemiologic, regulatory, and access-related information. Secondary research should include peer-reviewed clinical trial publications, liver cancer treatment guidelines, regulatory documents, public health databases, cancer registry outputs, hepatitis surveillance data, clinical practice recommendations, and health technology assessment reports. Priority evidence sources include randomized trials, meta-analyses, real-world cohort studies, systematic reviews, pharmacovigilance data, and consensus statements from recognized liver disease and oncology organizations.

Primary research should involve structured interviews with medical oncologists, hepatologists, interventional radiologists, radiation oncologists, pathologists, clinical pharmacists, payer experts, patient advocacy stakeholders, and hospital administrators. These interviews help validate treatment adoption patterns, barriers to access, referral bottlenecks, toxicity management practices, sequencing decisions, and regional variations in care. Analytical triangulation should be used to reconcile clinical evidence, real-world practice, and policy conditions without relying on unsupported assumptions.

The methodology should also evaluate treatment pathways by disease stage, liver function status, eligibility for immunotherapy, viral hepatitis status, performance status, portal hypertension, bleeding risk, and availability of locoregional intervention. Data quality should be assessed through source credibility, publication recency, population relevance, sample size, endpoint validity, and consistency across geographies. Ethical and compliance considerations are essential when interpreting patient-level data, particularly in AI applications, real-world evidence studies, registry linkage, and digital health platforms.

Conclusion

Unresectable hepatocellular carcinoma is a high-priority area in liver cancer care because it combines significant clinical complexity, late-stage presentation, underlying liver disease, and rapidly evolving treatment options. The field is being reshaped by immunotherapy-based combinations, targeted therapies, advanced locoregional techniques, improved imaging, multidisciplinary treatment planning, and emerging artificial intelligence applications. At the same time, prevention and surveillance remain central because many cases are linked to modifiable or manageable risk factors, including hepatitis B, hepatitis C, alcohol-related liver disease, obesity, diabetes, and cirrhosis.

Regional and country-level differences in viral hepatitis prevalence, metabolic risk, healthcare infrastructure, reimbursement, specialist access, imaging capacity, and screening programs strongly influence patient outcomes. Industry stakeholders that focus on earlier detection, validated innovation, equitable access, robust real-world evidence, and integrated care delivery will be best positioned to address the unmet needs of patients with unresectable hepatocellular carcinoma. Sustainable progress will depend on aligning clinical evidence with practical implementation across diverse health systems.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Unresectable Hepatocellular Carcinoma Market, by Therapy Type

• 7.1. Introduction
• 7.2. Radiation Therapy
  • 7.2.1. Proton Therapy
  • 7.2.2. External Beam Radiation Therapy
• 7.3. Locoregional Therapy
  • 7.3.1. Transarterial Chemoembolization
  • 7.3.2. Transarterial Radioembolization
• 7.4. Systemic Therapy
  • 7.4.1. Targeted Therapy
  • 7.4.2. Immunotherapy
  • 7.4.3. Combination Therapy

8. Unresectable Hepatocellular Carcinoma Market, by Line Of Therapy

• 8.1. Introduction
• 8.2. First Line
• 8.3. Second Line
• 8.4. Third Line

9. Unresectable Hepatocellular Carcinoma Market, by Route of Administration

• 9.1. Introduction
• 9.2. Intravenous
• 9.3. Oral

10. Unresectable Hepatocellular Carcinoma Market, by Mechanism of Action

• 10.1. Introduction
• 10.2. Angiogenesis Inhibition
• 10.3. Immune Modulation
• 10.4. Tumor Cell Proliferation Inhibition
• 10.5. Apoptosis Induction

11. Unresectable Hepatocellular Carcinoma Market, by End User

• 11.1. Introduction
• 11.2. Home Care Settings
• 11.3. Hospitals
• 11.4. Specialty Clinics

12. Unresectable Hepatocellular Carcinoma Market, by Distribution Channel

• 12.1. Introduction
• 12.2. Hospital Pharmacies
• 12.3. Online Pharmacies
• 12.4. Retail Pharmacies

13. Unresectable Hepatocellular Carcinoma Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Unresectable Hepatocellular Carcinoma Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Unresectable Hepatocellular Carcinoma Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. FPNV Positioning Matrix, 2025
• 16.3. Market Concentration Analysis, 2025
  • 16.3.1. Concentration Ratio (CR)
  • 16.3.2. Herfindahl Hirschman Index (HHI)
• 16.4. Recent Developments & Impact Analysis, 2025
• 16.5. Product Portfolio Analysis, 2025
• 16.6. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. AbbVie Inc.
• 17.2. Amgen Inc.
• 17.3. AstraZeneca PLC
• 17.4. Bayer AG
• 17.5. Bristol-Myers Squibb Company
• 17.6. CStone Pharmaceuticals
• 17.7. Daiichi Sankyo Company, Limited
• 17.8. Eisai Co., Ltd.
• 17.9. Eli Lilly and Company
• 17.10. Exelixis, Inc.
• 17.11. F. Hoffmann-La Roche Ltd
• 17.12. Gilead Sciences, Inc.
• 17.13. GlaxoSmithKline plc
• 17.14. Innovent Biologics, Inc.
• 17.15. Ipsen S.A.
• 17.16. Jazz Pharmaceuticals, Inc.
• 17.17. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
• 17.18. Johnson & Johnson Services, Inc
• 17.19. Kyowa Kirin Co., Ltd.
• 17.20. Merck KGaA
• 17.21. Novartis AG
• 17.22. Ono Pharmaceutical Co., Ltd.
• 17.23. Pfizer Inc.
• 17.24. Shanghai Junshi Biosciences Co., Ltd.
• 17.25. Takeda Pharmaceutical Company Limited
• 17.26. Teva Pharmaceutical Industries Ltd.
• 17.27. Zai Lab Limited